As an example, in the CENTRIC phase III clinical trial, cilengitide (an αvβ3/β5 specific inhibitor), administered in combination with the Stupp protocol in GBM with a methylated MGMT promoter, failed to show improved outcomes, although previous phase II studies had encouraging results [14]. Here, MGMT is linked to glioblastoma.